Skip to content

SALVAGE Trial (Safety And cLinical Value of AutoloGous rEinfusion)

SALVAGE Trial (Safety And cLinical Value of AutoloGous rEinfusion): A Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing Intraoperative Cell Salvage Versus No Cell Salvage in Adult Spinal Deformity Surgery

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07712666
Acronym
SALVAGE
Enrollment
146
Registered
2026-07-17
Start date
2026-11-01
Completion date
2029-08-01
Last updated
2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Spinal Deformity Surgery

Brief summary

The investigator hypothesizes intraoperative salvaged red blood cells are a poor substitute for allogenic packed red blood cell transfusions. In addition to providing inadequate resuscitation, salvaged red blood cells can increase the rate of complications, including postoperative electrolyte abnormalities, thrombocytopenia, anemia, and coagulopathy.

Detailed description

The goals of this study would therefore be to: 1. Determine the impact of intraoperative salvaged red blood cells on resuscitation and whether the return of salvaged red blood cells decreases the amount of intraoperative and postoperative allogenic packed red blood cell transfusions, both in terms of whether any allogenic blood product was provided and the number of units transfused during the hospital stay. 2. Compare complication rates and other secondary outcomes between patients who receive salvaged red blood cells versus those who did not, including infection, acute kidney injury, thrombocytopenia, liver injury, cardiac events, thrombotic events, pulmonary complications, length of hospital stay, discharge disposition, and 30-day readmission rates. 3. Determine if there's a threshold of transfused cell salvage blood that may be beneficial (e.g. \<300ml) and avoids complications.

Interventions

Using Cell Saver during surgery

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \>18 years of age undergoing adult thoracolumbar spinal deformity surgery as defined by one or more of the following radiographic criteria: 1) sagittal vertical axis \> 15 cm, pelvic incidence (PI) minus lumbar lordosis (LL) \> 25°, T1 pelvic angle \> 30°, thoracic scoliosis \> 70°, thoracolumbar/lumbar scoliosis \> 50°, or global coronal alignment \> 7 cm; 2) one or more of the following surgical criteria: posterior spinal fusion \> 12 levels, 3-column osteotomy (3CO), or anterior-column reconstruction; or 3) age \> 65 years and undergoing a minimum of 7 levels of spinal instrumentation surgery (geriatric criteria).

Exclusion criteria

* Patients with active spinal infection, neoplasm, acute trauma, neuromuscular etiology, syndromic scoliosis, prisoners, and pregnant patients

Design outcomes

Primary

MeasureTime frameDescription
Measure the impact of intraoperative salvaged red blood cells on resuscitation2 yearsMeasure the impact of intraoperative salvaged red blood cells on resuscitation and whether the return of salvaged red blood cells decreases the amount of intraoperative and postoperative allogenic packed red blood cell transfusions to confirm if any allogenic blood product was provided.

Secondary

MeasureTime frameDescription
Compare complication rates and other secondary outcomes2 yearsVia chart review, compare infection, acute kidney injury, thrombocytopenia, liver injury, cardiac events, thrombotic events, pulmonary complications, length of hospital stay, discharge disposition, and 30-day readmission rates of patients who receive salvaged red blood cells versus those who did not.
Measure the number of salvaged blood cell units transfused during the hospital stay.2 yearsMeasure the number of salvaged blood cell units transfused during the hospital stay.

Contacts

CONTACTLaura Westendorf
westendorf.laura@mayo.edu507-284-8167
CONTACTJustice Story
story.justice@mayo.edu507-422-5528
PRINCIPAL_INVESTIGATORAnthony Mikula, M.D.

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 12, 2026